

Dalcetrapib

Catalog No: tcsc0916



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

211513-37-0

Formula:

$C_{23}H_{35}NO_2S$

Pathway:

Metabolic Enzyme/Protease

Target:

CETP

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Alternative Names:

JTT-705;RO4607381

Observed Molecular Weight:

389.59

Product Description


Dalcetrapib (JTT-705; RO-4607381) is a rhCETP inhibitor with IC₅₀ of 0.2 μ M that increases the plasma HDL cholesterol.

IC₅₀ value: 0.2 μ M [1]

Target: CETP

in vitro: Dalcetrapib modulates CETP activity. Dalcetrapib induces a conformational change in CETP, when added to human plasma. CETP-induced pre- β -HDL formation in human plasma is unchanged by Dalcetrapib ≤ 3 μ M and increased at 10 μ M. Dalcetrapib statistically and significantly increases pre- β -HDL formation [1]. Dalcetrapib achieves 50% inhibition of CETP activity in human plasma at a concentration of 9 μ M [2]. Dalcetrapib inhibits the CETP activity of media in HepG2 in a dose-dependent manner [3].

in vivo: Treatment with Dalcetrapib leads to significant increases in HDL-C levels. In hamsters injected with [3H]cholesterol-labeled autologous macrophages Dalcetrapib significantly increases fecal elimination of both [3H]neutral sterols and [3H]bile acids. Dalcetrapib increases plasma HDL-[3H]cholesterol [1]. Dalcetrapib has 95% inhibition of CETP activity in male Japanese white rabbits at an oral dose of 30 mg/kg. Dalcetrapib increases the plasma HDL cholesterol level by 27% and 54%, respectively, when given at oral doses of 30 mg/kg or 100 mg/kg once a day for 3 days to male Japanese white rabbits [2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!